SEARCH

SEARCH BY CITATION

References

  • 1
    Eheman, C., S. J. Henley, R. Ballard-Barbash, E. J. Jacobs, M. J. Schymura, A. M. Noone, et al. 2012. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118:23382366.
  • 2
    DeSantis, C., R. Siegel, P. Bandi, and A. Jemal. 2011. Breast cancer statistics, 2011. CA Cancer J. Clin. 61:409418.
  • 3
    Vilaprinyo, E., T. Puig, and M. Rue. 2012. Contribution of early detection and adjuvant treatments to breast cancer mortality reduction in Catalonia. Spain. PloS one 7:e30157.
  • 4
    Simonet, W. S., D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Luthy, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309319.
  • 5
    Tsuda, E., M. Goto, S. Mochizuki, K. Yano, F. Kobayashi, T. Morinaga, et al. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234:137142.
  • 6
    Boyce, B. F., and L. Xing. 2007. Biology of RANK, RANKL, and osteoprotegerin. Arthritis research & therapy 9(Suppl. 1):S1.
  • 7
    Jonkers, J., and P. W. Derksen. 2007. Modeling metastatic breast cancer in mice. Journal of mammary gland biology and neoplasia 12:191203.
  • 8
    Kozlow, W., and T. A. Guise. 2005. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. Journal of mammary gland biology and neoplasia 10:169180.
  • 9
    Body, J. J., P. Greipp, R. E. Coleman, T. Facon, F. Geurs, J. P. Fermand, et al. 2003. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887892.
  • 10
    Chanda, D., T. Isayeva, S. Kumar, G. P. Siegal, A. A. Szafran, K. R. Zinn, et al. 2008. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Molecular therapy: the journal of the American Society of Gene Therapy 16:871878.
  • 11
    Holen, I., S. S. Cross, H. L. Neville-Webbe, N. A. Cross, S. P. Balasubramanian, P. I. Croucher, et al. 2005. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival? Breast Cancer Res. Treat. 92:207215.
  • 12
    Rachner, T. D., M. Schoppet, U. Niebergall, and L. C. Hofbauer. 2008. 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. Biochem. Biophys. Res. Commun. 368:736741.
  • 13
    Labovsky, V., V. B. Vallone, L. M. Martinez, J. Otaegui, and N. A. Chasseing. 2012. Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer cell international 12:29.
  • 14
    Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. The Journal of biological chemistry 271:1268712690.
  • 15
    Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673682.
  • 16
    Zauli, G., E. Melloni, S. Capitani, and P. Secchiero. 2009. Role of full-length osteoprotegerin in tumor cell biology. Cellular and molecular life sciences: CMLS 66:841851.
  • 17
    Root, D. E., N. Hacohen, W. C. Hahn, E. S. Lander, and D. M. Sabatini. 2006. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods 3:715719.
  • 18
    Zijlstra, A., R. Mellor, G. Panzarella, R. T. Aimes, J. D. Hooper, N. D. Marchenko, et al. 2002. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 62:70837092.
  • 19
    Barrett, T., D. B. Troup, S. E. Wilhite, P. Ledoux, D. Rudnev, C. Evangelista, et al. 2009. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res. 37:D885D890.
  • 20
    Revet, I., G. Huizenga, A. Chan, J. Koster, R. Volckmann, P. van Sluis, et al. 2008. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp. Cell Res. 314:707719.
  • 21
    Cerami, E., J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery 2:401404.
  • 22
    Gao, J., B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling 6:pl1.
  • 23
    Fisher, J. L., R. J. Thomas-Mudge, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, et al. 2006. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66:36203628.
  • 24
    Cross, S. S., Z. Yang, N. J. Brown, S. P. Balasubramanian, C. A. Evans, J. K. Woodward, et al. 2006. Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? International journal of cancer Journal international du cancer 118:19011908.
  • 25
    Rachner, T. D., P. Benad, M. Rauner, C. Goettsch, S. K. Singh, M. Schoppet, et al. 2009. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J. Cell. Biochem. 108:106116.
  • 26
    Zinonos, I., A. Labrinidis, M. Lee, V. Liapis, S. Hay, V. Ponomarev, et al. 2011. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 26:630643.
  • 27
    Secchiero, P., F. Corallini, A. P. Beltrami, C. Ceconi, V. Bonasia, A. Di Chiara, et al. 2010. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:274277.
  • 28
    Glondu, M., E. Liaudet-Coopman, D. Derocq, N. Platet, H. Rochefort, and M. Garcia. 2002. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene 21:51275134.
  • 29
    Liaudet-Coopman, E., M. Beaujouin, D. Derocq, M. Garcia, M. Glondu-Lassis, V. Laurent-Matha, et al. 2006. newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett. 237:167179.
  • 30
    Toffoli, B., R. J. Pickering, D. Tsorotes, B. Wang, S. Bernardi, P. Kantharidis, et al. 2011. Osteoprotegerin promotes vascular fibrosis via a TGF-beta1 autocrine loop. Atherosclerosis 218:6168.
  • 31
    Ney, J. T., I. Juhasz-Boess, F. Gruenhage, S. Graeber, R. M. Bohle, M. Pfreundschuh, et al. 2013. Genetic polymorphism of the OPG gene associated with breast cancer. BMC cancer 13:40.
  • 32
    Ito, R., H. Nakayama, K. Yoshida, K. Kuraoka, J. Motoshita, N. Oda, et al. 2003. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 443:146151.